KD-025 (Nanjing KAEDI Biotech)

N/A

Report date: 2023/03/21 14:15:29

Base Information

Drug NameKD-025 (Nanjing KAEDI Biotech)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionNKG2D ligands antagonists
TargetsNKG2D ligands
Therapy Area/IndicationsSolid tumoursColonic NeoplasmsCarcinoma, Hepatocellular +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Kaidi Medical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Kaidi Medical Technology Co Ltd
Inactive CompaniesFudan University
Active IndicationsSolid tumours
Inactive IndicationsColonic NeoplasmsCarcinoma, HepatocellularMedulloblastoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A